PAKOLA STEVE sold $29K of RGNX
PAKOLA STEVE (Chief Medical Officer) sold 2,161 shares of REGENXBIO Inc. (RGNX) at $13.64 on 2026-07-02 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed sale is pre-arranged under a Rule 10b5-1 plan, reducing the likelihood that it reflects new, time-sensitive negative information.
Market read
Traders may note the insider sale for sentiment monitoring, but the filing alone does not provide a new fundamental catalyst.
What to watch
The article provides only the sale details; it does not include context like total insider holdings changes over time, other concurrent filings, or any company-specific news.
Background
The article is a SEC Form 4 insider transaction disclosure for REGENXBIO Inc. (RGNX).
Ticker impact
RGNX disclosed a Form 4 showing CMO Pakola Steve sold 2,161 shares at $13.64 on 2026-07-02 under a 10b5-1 plan.
Likely limited near-term impact; any effect would be sentiment-driven and typically fades unless paired with other negative news.
The filing is a Form 4 insider transaction with explicit 10b5-1 pre-arrangement and no accompanying operational/regulatory/clinical update in the text.
Market effects
No sector read-through provided; this is company-specific insider transaction data only.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, repeated insider selling can still be viewed as a mild bearish sentiment input by some traders.
Key entities
- issuerREGENXBIO Inc.
Company subject of the Form 4 insider transaction disclosure.
- insiderPakola Steve
Chief Medical Officer who sold shares under a 10b5-1 plan.
